AI Drug Discovery
Page 1 • 3 itemsUnlock AI drug discovery insights. Track global pharma market trends, investment opportunities, and regulatory impacts for your BD strategy.
XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment
XtalPi and PharmaEngine's AI-discovered PRMT5 inhibitor PEP08 starts Phase I solid tumor trial enrollment, marking a key milestone in synthetic lethality cancer treatment.
Vasa Therapeutics Partners with Eli Lilly's TuneLab AI Platform for CAMKII Inhibitor Development
Vasa Therapeutics announces partnership with Eli Lilly's TuneLab AI platform to accelerate CAMKII delta inhibitor development for cardiovascular disorders.
AI FDA Breakthrough Therapy: How AI Accelerates Oncology Drug Designations
Explore the transformative role of AI in oncology, focusing on how it expedites FDA breakthrough therapy designations for drugs like XYZ Drug in cancer treatment.